235 related articles for article (PubMed ID: 15992694)
1. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
[TBL] [Abstract][Full Text] [Related]
2. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
3. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Lancet; 2000 May; 355(9215):1588-96. PubMed ID: 10821362
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Glimelius B; Dahl O; Cedermark B; Jakobsen A; Bentzen SM; Starkhammar H; Grönberg H; Hultborn R; Albertsson M; Påhlman L; Tveit KM;
Acta Oncol; 2005; 44(8):904-12. PubMed ID: 16332600
[TBL] [Abstract][Full Text] [Related]
6. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
7. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
; Gray R; Barnwell J; McConkey C; Hills RK; Williams NS; Kerr DJ
Lancet; 2007 Dec; 370(9604):2020-9. PubMed ID: 18083404
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.
Kerr DJ; Gray R; McConkey C; Barnwell J
Ann Oncol; 2000 Aug; 11(8):947-55. PubMed ID: 11038030
[TBL] [Abstract][Full Text] [Related]
15. Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Rougier P; Nordlinger B
Ann Oncol; 1993; 4 Suppl 2():21-8. PubMed ID: 8353101
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Cafiero F; Gipponi M; Lionetto R;
J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
[TBL] [Abstract][Full Text] [Related]
17. [Progress of adjuvant chemotherapy in colon cancer].
Toge T
Gan To Kagaku Ryoho; 1996 Apr; 23(5):554-9. PubMed ID: 8678512
[TBL] [Abstract][Full Text] [Related]
18. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Taal BG; Van Tinteren H; Zoetmulder FA;
Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
[TBL] [Abstract][Full Text] [Related]
20. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
